Bizmarketeer - Webinars & Events
Webinars & Events 8 Min Read
In this episode of Tesseract Talks, host John K. Thompson, data and AI thought leader and author of The Path to AGI, speaks with Dr. Mark Mackey, Chief Scientific Officer at Cresset, who has spent over two decades building computational tools for pharmaceutical R&D, to explore how AI and computational chemistry are reshaping drug discovery.
The conversation centers on one of the most complex and underappreciated aspects of drug development: ensuring that a molecule not only works biologically but can actually function as a viable drug inside the human body. Mark introduces the concept of ADME (absorption, distribution, metabolism, excretion), explaining that success in drug discovery goes far beyond finding a molecule that binds to a target protein. The real challenge lies in predicting whether that molecule survives digestion, reaches the bloodstream, avoids breakdown, enters cells, and performs its intended function without harmful side effects.
From there, the discussion shifts to the limitations of traditional computational approaches and how modern AI, particularly machine learning and deep learning, is improving predictive accuracy. Rather than replacing scientists, AI acts as a powerful pattern-recognition engine, helping researchers decide which molecules are worth synthesizing and testing. Even modest improvements in prediction accuracy can significantly reduce the number of experiments needed, lowering costs and accelerating timelines.
Mark also highlights the growing industrialization of drug discovery. What was once a slow process is evolving into a more automated pipeline, combining generative AI for molecule design, predictive models for screening, and robotics for synthesis. This shift mirrors the transition from handcrafted production to scalable manufacturing, enabling faster iteration cycles and more efficient experimentation.
The episode closes with a grounded perspective on AI’s role in life sciences. While AI is already delivering value in optimization, automation, and cost reduction, it is not a silver bullet. The biggest bottleneck remains our incomplete understanding of human biology, which is the primary reason why most drugs fail in clinical trials. The real opportunity lies in using AI to make failure cheaper and faster, rather than eliminating it entirely.
Takeaways